🔗 Share this article

As the United States proceeds with unprecedented revisions to its immunization recommendations, one figure appears somewhat surprisingly: Høeg, an American of Danish descent physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccinations throughout the pandemic and has focused upon alleged fatalities after Covid immunization in her brief tenure at the FDA.

Proposed Shifts to Childhood Vaccine Schedule

Public health authorities planned to unveil major revisions to the pediatric immunization program earlier this month, bringing the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US at odds with a large portion of the world with no evidence for improved outcomes. This reveal has been postponed until the new year.

In place of the director of the vaccine center, Høeg is listed to speak at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth individual to lead the center this year.

A New Direction at the FDA

The acting appointment may indicate a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it suggests a greater focus upon rolling back long-standing vaccines at the FDA.

The new acting director has frequently advocated for ending certain pediatric immunization guidelines in the US to become more in line with Denmark, a society with comprehensive healthcare and a number of inhabitants about the size of the state of Wisconsin.

To date statements, she has kept her attention on vaccination policy – usually the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Doubts Over Qualifications

The appointee has little discernible experience in medication creation, regulation or leadership, which has been standard for previous leaders of the CBER. She has been employed at the FDA as a top consultant to the agency head and CBER since earlier this year.

“It seems she lacks to have the necessary background” for running the CDER, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in running a large organization. She is not an expert in industry regulation.”

Former heads of the center would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, noted a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that previous people who ran CBER have had.”

The drug center has an immense range of responsibilities at the FDA, she stated.

“Everybody just zeroes in on the innovative therapies, but the generic program authorizes thousands of generic medications. There is also a biosimilars program, over-the-counter program and other areas, and every single one have to be supervised,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Furthermore, a substantial leadership aspect to the role, which oversees in excess of 5,000 staff members. “It’s a enormous leadership role, if you execute it properly,” the former official concluded.

Response and Contentious Programs

When asked about questions about Dr. Høeg's qualifications and whether this appointment indicates increased cooperation among FDA leaders on vaccines, a representative responded that the “inquiries are based on incorrect presumptions”.

“Her resume matches the responsibilities of her role,” the representative explained, pointing to the months Dr. Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a disputed rapid medication authorization process that allegedly worried her former heads. “By what process are these medications being chosen for this voucher program? Who is making the calls?” Dr. Howard said. “There is a lot of confidentiality occurring at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards more relaxed rules of all drugs, aside from shots.”

Established Track Record on Vaccines

Concerning immunizations, Høeg has a clearer, if concerning, past, Howard said. She published a analysis using unverified volunteer-provided data to determine the incidence of heart inflammation following COVID-19 immunization. She counseled the state of Florida top health official Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccines are more dangerous than they are.

Among her “desired changes” for the current federal leadership encompassed revising guidelines for novel immunizations and discontinuing “non-essential” immunizations, she remarked post-election on a podcast. At the agency, Høeg has allegedly suggested barring teenage boys from getting COVID-19 vaccinations.

“She’s an complete true believer who commences with her preconceived notions and works backwards to retrofit the data in a highly deceptive, untruthful manner,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other contrarians, {like|